Lifecore Biomedical, Inc.
NASDAQLifecore Biomedical reported Q1 fiscal 2026 results on May 6, posting sales of $23.2 million — well short of the $26.5 million consensus estimate — alongside a loss per share of $0.43 versus an expected $0.24 loss. Despite the miss, the company held its full-year sales guidance of $120–$125 million. That guidance reaffirmation is the central tension heading into next week: the stock…
Snapshot as of 6 May 2026
Lifecore Biomedical reported Q1 fiscal 2026 results on May 6, posting sales of $23.2 million — well short of the $26.5 million consensus estimate — alongside a loss per share of $0.43 versus an expected $0.24 loss.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for LFCR — free to start on ORTEX.
Sign up for free →Open LFCR on ORTEX